文献速递骨软组织肉瘤与黑色素瘤

现行免疫肿瘤学时代肿瘤浸润淋巴细胞疗法在晚期皮肤黑色素瘤中的疗效:更新的系统综述与荟萃分析

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
PubMed 文献 · Ann Oncol · 2024-07-23

本更新荟萃分析纳入13项高剂量白介素-2研究、617例有总生存信息的晚期皮肤黑色素瘤患者,评估肿瘤浸润淋巴细胞过继细胞治疗(TIL-ACT)的总生存及既往抗PD-(L)1治疗的影响。既往抗PD-(L)1组与未接受组中位总生存分别为17.5个月与16.3个月(log-rank P=0.53),客观缓解率分别为34%与44%(P=0.15),完全缓解率两组均为10%(P=0.45)。结论认为既往抗PD-(L)1治疗不影响TIL-ACT的临床缓解或生存获益。

要点

  • 既往抗PD-(L)1组与未接受组中位总生存17.5个月 vs 16.3个月,无显著差异(log-rank P=0.53)。
  • 客观缓解率既往抗PD-(L)1组34% vs 未接受组44%,无统计学显著差异(P=0.15)。
  • 完全缓解率两组均为10%,无统计学显著差异(P=0.45)。

核心结论

  • 既往抗PD-(L)1治疗对晚期皮肤黑色素瘤患者TIL-ACT的临床缓解或生存获益无影响。
  • 抗PD-(L)1治疗后,TIL疗法在二线治疗中的获益仍然存在。
  • 作者认为数据强化了TIL-ACT应被视为抗PD-(L)1治疗失败的转移性黑色素瘤患者二线治疗选择的证据。

研究设计与样本

  • 在PubMed进行综合检索,截止2024年2月29日。
  • 本荟萃分析聚焦于包含高剂量白介素-2的研究,患者数较此前截止2018年12月的荟萃分析翻倍,并以总生存为主要终点。
  • 共纳入13项高剂量白介素-2研究,617例患者有总生存信息。
  • 客观缓解率、完全缓解率和缓解持续时间為次要终点。
  • 采用表格、Kaplan-Meier曲线和森林图汇总结果,客观缓解率与完全缓解率的合并估计来自固定或随机效应模型。

主要发现

  • 既往抗PD-(L)1治疗组(n=238)中位总生存17.5个月(95%CI 13.8-20.5个月)vs 未接受组(n=379)16.3个月(95%CI 14.2-20.6个月),log-rank P=0.53。
  • 既往抗PD-(L)1治疗组客观缓解率34%(95%CI 16%-52%)vs 未接受组44%(95%CI 37%-51%),P=0.15。
  • 两组完全缓解率合并估计均为10%,P=0.45。
  • 两组间客观缓解率或完全缓解率均未观察到统计学显著差异。

临床怎么用

  • 作者认为TIL-ACT应被视为抗PD-(L)1治疗失败的转移性黑色素瘤患者的二线治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) has consistently shown efficacy in advanced melanoma. New results in the field provide now the opportunity to assess overall survival (OS) after TIL-ACT and to examine the effect of prior anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] therapy on its efficacy. METHODS: A comprehensive search was conducted in PubMed up to 29 February 2024. Ιn this meta-analysis we focused on studies including high-dose interleukin 2, doubling the patient numbers from our previous meta-analysis conducted up to December 2018 and using OS as the primary endpoint. Objective response rate (ORR), complete response rate (CRR), and duration of response were secondary endpoints. Findings are synthesized using tables, Kaplan-Meier plots, and forest plots. Pooled estimates for ORR and CRR were derived from fixed or random effects models. RESULTS: A total of 13 high-dose interleukin 2 studies were included in this updated meta-analysis, with OS information available for 617 patients. No difference was found in median OS between studies with prior anti-PD-(L)1 treatment {n = 238; 17.5 months [95% confidence interval (CI) 13.8-20.5 months]} and without [n = 379; 16.3 months (95% CI 14.2-20.6 months)] (log-rank P = 0.53). ORR was estimated to be 34% (95% CI 16%-52%) and 44% (95% CI 37%-51%), for the studies with and without prior anti-PD-(L)1, respectively. The pooled estimate for CRR was 10% for both groups. No statistically significant difference was observed between the two groups, either for ORR (P = 0.15) or CRR (P = 0.45). CONCLUSIONS: Prior anti-PD-(L)1 treatment has no effect on the clinical response or survival benefit from TIL-ACT in advanced cutaneous melanoma. The benefit of TIL therapy in the second-line setting is also present after anti-PD-(L)1 treatment. Our data reinforce the evidence that TIL-ACT should be considered as a treatment of choice in second line for metastatic melanoma patients failing anti-PD-(L)1 therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Martín-Lluesma S, Svane IM, Dafni U, et al. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Ann Oncol. 2024. PMID: 39053767. doi:10.1016/j.annonc.2024.07.723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。